Kimelman & Baird, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Kimelman & Baird, LLC
- $1.21 Trillion
- Q2 2024
A detailed history of Kimelman & Baird, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Kimelman & Baird, LLC holds 54 shares of REGN stock, worth $44,734. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54Holding current value
$44,734% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,494Shares Held
84.9MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.45 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$7 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$6.2 Billion0.65% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.01 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.84 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $88.8B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...